The Legacy Builders Young Investigator Grant
Aberrant BER confers sensitivity to PARP Inhibitors in pediatric AML
Despite overall cure rates of pediatric cancer reaching nearly 80%, the overall survival of children diagnosed with acute myeloid leukemia (AML) is approximately 60%. This study evaluates a drug commonly used in breast cancer called a PARP inhibitor in pediatric patients with relapsed AML. It seeks to exploit faults in DNA repair and identify those patients with cancers where these faults are present so that we can provide targeted treatment and improve outcomes for these patients.
This Project By The Numbers
Years Active3 Years